Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Small Cell Lung Carcinoma × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Hodgkin Disease 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 39 Etoposide 33 Cisplatin 21 Topotecan 20 Nivolumab 13 atezolizumab 10 pembrolizumab 9 Ipilimumab 9 durvalumab 8 Paclitaxel 7 Irinotecan 7 rovalpituzumab tesirine 5 Radiosurgery 5 trioctyl phosphine oxide 4 trilaciclib 4 berzosertib 4 Sunitinib 4 Platinum 4 Pemetrexed 4 PM 01183 4 veliparib 3 tremelimumab 3 olaparib 3 carfilzomib 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 Drug Therapy 3 Doxorubicin 3 Dexamethasone 3 Bevacizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03417895 2024-08-07

PASSION

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡